VivoSeq
Immunology

Peanut Allergy

3

Pipeline Programs↗

3

Active Trials↗

2

Companies Involved↗

Peanut Allergy is an early-stage landscape with 3 programs across 2 companies. The most active players are AstraZeneca, Moonlight Therapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 2M

Moonlight Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Recruiting3 · 100%

Clinical Trials

Trial Activity

Safety of MOON101 for the Treatment of Peanut Allergy
Recruiting·MMoonlight Therapeutics, Inc.·Phase 1·NCT07580898·40 enrolled
Efficacy of Tezepelumab in Peanut Oral Immunotherapy: a Double-Blind, Randomized, Placebo-Controlled Trial
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT07015996·62 enrolled
Prospective Study to Identify Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in Patients With Elevated Total Serum IgE Levels and Atopic Dermatitis
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03835767·200 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)